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Objective. Anti-carbamylated protein (anti-CarP) antibodies are associated with the risk and severity of rheumatoid arthritis (RA) and are primarily directed against fibrinogen. The lack of understanding of antiCarP antibody reactivity has limited analysis of the immunopathogenic associations in RA. To address this shortcoming, we mapped anti-CarP antibody epitope reactivity in RA patient sera.
Methods. Immunoblotting identified a patient serum sample with specific reactivity to the carbamylated human fibrinogen b-chain. Liquid chromatography mass spectrometry (LC-MS) identified sites of homocitrullines (carbamylated lysines) present in the human fibrinogen b-chain. The reactivity of an anti-CarP antibody-positive cohort to specific peptides containing carbamylated lysines was determined by enzyme-linked immunosorbent assay, through direct binding (n 5 63 sera) and by competition assays (n 5 40 sera).
Results. Serum with specific reactivity to carbamylated, but not citrullinated, fibrinogen b-chain was identified in a specimen obtained from an RA patient. LC-MS identified carbamylation of 9 of 34 lysines in the human fibrinogen b-chain. Mapping of immunoreactivity to tryptic peptide fragments demonstrated several candidate carbamylated epitopes that were confirmed by competition experiments. Peptides containing a homocitrulline at position 83 appeared to be an immunodominant epitope in some RA patient sera, with additional reactivity to peptides containing homocitrullines at positions 52, 264, 351, 367, and 374.
Conclusion. Anti-CarP antibodies appear to preferentially target specific regions of the human fibrinogen b-chain that contain homocitrullines. Interestingly, humoral immunoreactivity appears to be relatively restricted in some patients, which may enable detection of specific relationships with disease phenotype.
The breaking of tolerance to citrullinated proteins, represented by the emergence of anti-citrullinated protein antibodies (ACPAs), is strongly associated with the risk of rheumatoid arthritis (RA). ACPAs can be present for many years before the onset of clinical disease (1). Curiously, ACPAs appear to be specifically directed against many different citrullinated proteins (fibrinogen, vimentin, a-enolase, filaggrin, and histone) as well as being polyreactive through citrulline binding (2, 3) . Thus, ACPAs serve as a marker of disease risk, although no specific reactivity is associated with the onset of joint inflammation (2, 4) . With the onset of clinical disease, ACPA production can be demonstrated in the joint, with evidence of synovial affinity maturation (3, 5) . Clinically, the presence of ACPAs predicts a greater likelihood of erosive and extraarticular disease (6) .
In this context, homocitrullination of lysines (also referred to as carbamylation), a posttranslational modification similar to citrullination, has additionally been shown to be a target of autoantibodies (anti-carbamylated protein [anti-CarP] antibodies) in RA (7, 8) . This modification is similar to citrullination, with the same ureido functional group added to the primary amine group of lysine rather than arginine. In contrast to the enzymatic catalysis of arginine to citrulline mediated by peptidylarginine deiminase (PAD), the chemical carbamylation of lysine to homocitrulline occurs spontaneously through a reaction with cyanate that is enhanced through cyanate production mediated by myeloperoxidase (9) . Both PADI4 and myeloperoxidase reside in the azurophilic granules of neutrophils. Thus, both modifications are likely to occur in concert at sites of inflammation.
Anti-CarP antibodies were discovered using an enzyme-linked immunosorbent assay (ELISA) with immobilized carbamylated fetal calf serum (FCS) in ACPA-positive and ACPA-negative RA sera (7) . Similar to ACPAs, anti-CarP antibodies were shown to precede the onset of synovitis as well as predict radiographic progression (7, 10) . In contrast to ACPAs, anti-CarP antibodies appear to be primarily directed against carbamylated human fibrinogen (11).
The notion that an autoantibody against a single posttranslationally modified protein (fibrinogen) is associated with disease risk and progression would potentially give anti-CarP antibodies an advantage as a biomarker relative to the polyreactivity seen with ACPAs. However, advancement in the understanding of anti-CarP antibodies has been limited by the lack of understanding of their cross-reactivity with ACPAs. Given the similarity of the posttranslational modification, with the ureido functional group added to the primary amine group of a basic (lysine versus arginine) amino acid, it would not be surprising to observe that anti-CarP antibodies and ACPAs cross-react (12) . Nevertheless, adsorption and competition studies have suggested the presence of antibodies that appear to be specific for each posttranslational modification (13) .
These issues impact the ability to fully assess the role of anti-CarP antibodies in RA pathogenesis or as a biomarker of disease severity. Are the anti-CarP antibodies that appear in a preclinical setting a subset of cross-reactive ACPAs? Similarly, is the association of anti-CarP antibodies with radiographic disease enhanced or diminished by the presence of cross-reactive ACPAs? Do specific antiCarP antibodies change with disease activity, in contrast to ACPAs? Moreover, is the apparent restriction of anti-CarP antibodies to carbamylated fibrinogen inherent or a function of an assay biased toward examining fibrinogen? Each of these issues would be best addressed by understanding the specificity and selectivity of anti-CarP antibodies. In this report, we present data that lays the foundation for addressing these questions by demonstrating that antiCarP antibodies include highly specific antibodies directed against a homocitrullinated peptide in the fibrinogen bchain. Surprisingly, in some patients, this peptide appears to constitute an immunodominant epitope.
PATIENTS AND METHODS
Patient samples. Approval to collect patient samples and clinical data was obtained from the Dartmouth College Committee for the Protection of Human Subjects. Serum samples (n 5 63) were obtained from patients seen at the Rheumatology Clinic of the Dartmouth-Hitchcock Medical Center who were classified as having RA seropositive for rheumatoid factor (RF) and/or ACPAs (with the exception of 2 seronegative RA patients who were strongly positive for anti-CarP antibodies). Serum samples were stored at 2808C as part of the Dartmouth Rheumatic Disease Biorepository. Samples that had high anti-CarP antibody reactivity were chosen, along with several others having a range of low anti-CarP antibody reactivity to no anti-CarP antibody reactivity.
Reagents, antibodies, and peptides. Fibrinogen ($98% purity) isolated from human plasma was obtained from Hyphen-BioMed (catalog no. PP001B). Citrullinated human fibrinogen was purchased from Cayman Chemical. Fibrinogen or FCS was carbamylated by treating with 1M KCN (Sigma) at 378C for 12 hours followed by extensive dialysis, as previously described (14) . Rabbit anti-carbamyl-lysine (anti-CBL) polyclonal antibody was purchased from Cell Biolabs. Horseradish peroxidase (HRP)-conjugated goat anti-human fibrinogen was purchased from Novus Biologicals (catalog no. NB600-927). Human fibrinogen b-chain peptides (GenBank accession no. P02675) with specified lysine or homocitrulline were synthesized (LifeTein) as either cyclized (using a cysteine-cysteine disulfide bond) or linear (see Table 1 ).
Fibrinogen analysis. The b-chain of carbamylated fibrinogen was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the band was cut out. In-gel tryptic digestion was performed, and analysis by liquid chromatography mass spectrometry (LC-MS) performed at the Yale Mass Spectrometry (MS) and Proteomics Resource of the W. M. Keck Foundation Biotechnology Resource Laboratory revealed 9 homocitrullines among 34 lysines. Subsequently, tryptic digestion was performed, and the peptides were purified by reverse-phase high-performance liquid chromatography (HPLC). Fractions were tested for reactivity by ELISA, using index patient serum. The identity of the peptides in fractions with reactivity were determined by MS/MS.
Anti-CarP antibodies and peptide ELISA. An anti-CarP antibody ELISA was performed as previously described (14) . The antigen of interest (carbamylated FCS, noncarbamylated FCS, or peptide [10 mg/ml]) was incubated overnight at 48C in flat-bottomed 96-well microplates (R&D Systems) and then washed and blocked using 1% bovine serum albumin. Serum specimens (1:100 dilution) were incubated for 2 hours at room temperature and washed, followed by incubation with HRPconjugated goat anti-human IgG (Bio-Rad). Following washing, tetramethylbenzidine substrate (R&D Systems) was added, and absorbance was measured with a BioTek spectrophotometer using wavelengths of 450-570 nm. Values obtained from noncarbamylated FCS were subtracted from carbamylated FCS values to yield the final antibody concentration. The positive cutoff was defined as 2 SD above the mean for 65 healthy controls.
In competition experiments, the peptide was preincubated with diluted serum at room temperature for 1 hour prior to addition to the wells. Initially, peptides were also added to noncarbamylated FCS, but because no change in background signal was observed, subsequent experiments used only noncarbamylated FCS without peptides as background. Maximal inhibition of reactivity occurred at peptide concentrations of 20 mg/ml; therefore, to ensure saturating conditions, a concentration of 50 mg/ml was used.
Immunoblots. Carbamylated fibrinogen, citrullinated fibrinogen, and native fibrinogen were loaded (1 mg) onto 12% SDS-PAGE gels, resolved by electrophoresis, and then were transferred to nitrocellulose and blocked overnight in 3% BSA in Tris buffered saline-Tween 20. The blots were incubated with CBL (1:1,000), HRP-conjugated goat anti-human fibrinogen (1 mg/ml), or patient sera at specified dilutions for 2 hours, washed, incubated with HRP-conjugated goat anti-human IgG secondary antibody (1:6,000), and then treated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher). Fluorescence was captured using an Alpha Innotech MultiImage III cabinet.
RESULTS
Anti-CarP antibodies specific for carbamylated fibrinogen. We identified a unique patient with refractory and erosive RA who had been persistently ACPA and RF negative yet exhibited strong anti-CarP antibody reactivity. We hypothesized that serum from this patient could be used to map epitopes of carbamylated fibrinogen without concern for ACPA cross-reactivity. Immunoblotting was performed against native, citrullinated, and carbamylated human fibrinogen, using this serum ( Figure 1A) . Human fibrinogen is a hexameric protein made up of 2 copies of the a-chain, b-chain, and g-chain. Using antisera (anti-CBL) specific for homocitrullines, we demonstrated reactivity in the a-chain, b-chain, and g-chain in carbamylated fibrinogen but not in native or citrullinated fibrinogen. Blotting with this serum exhibited specificity for carbamylated but not citrullinated or native fibrinogen b-chain (minor staining seen below the b-chain was likely a splice variant) (15) .
We blotted carbamylated fibrinogen or native fibrinogen with 11 additional anti-CarP antibody-positive RA patient sera to evaluate the commonality of b-chain specificity. Five sera did not have reactivity by immunoblotting (data not shown). The remaining 6 sera had reactivity to carbamylated but not native fibrinogen (see Supplementary Figure 1 Mapping homocitrullines and anti-CarP antibody reactivity in the human fibrinogen b-chain. The carbamylation sites in the fibrinogen b-chain were analyzed. Carbamylated human fibrinogen was resolved by SDS-PAGE, and the band corresponding to the fibrinogen b-chain was cut out, subjected to in-gel tryptic digestion, and analyzed by LC-MS. Of 34 lysines, 9 (52, 83, 160, 163, 264, 351, 353, 367, and 374) (26.5%) were identified as homocitrullines (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40098/abstract). Following tryptic digestion, peptides of the fibrinogen b-chain were purified by reverse-phase HPLC and analyzed by ELISA for reactivity, using serum from the index patient. One fraction had reactivity 2-4 times that of other reactive fractions and contained a single peptide (A 78 AATQKK 84 ) with a single carbamylated lysine at position 83 (designated D83).
Frequency of anti-CarP antibody reactivity with fibrinogen 77-87 D83. Cyclized peptides corresponding to amino acids 77-87 with or without homocitrulline at position 83 (Table 1) were analyzed by ELISA. RA patient sera (n 5 63) were analyzed for specific reactivity to the carbamylated peptide (values obtained for peptide 77-87 were subtracted from values obtained for peptide 77-87 D83) in relation to anti-CarP antibody reactivity ( Figures 1B and C) . We identified a value of .0 (a positive cutoff was not determined) in 22 patients (35%). Interestingly, although reactivity with this peptide did not correlate with anti-CarP Competition ELISA of peptides derived from the human fibrinogen b-chain. We studied the ability of carbamylated fibrinogen b-chain peptides to compete with binding to carbamylated FCS. We synthesized linear peptides with homocitrullines corresponding to sites conserved between human and bovine fibrinogen b-chain ( Table 1 ). The ability of linear and cyclized peptides (at saturating concentrations of 50 mg/ml) to compete for binding to anti-CarP antibody-FCS was analyzed using patient sera (n 5 40) with the highest anti-CarP antibody-FCS reactivity ( Figure 1D ). Little or no inhibition of anti-CarP antibody-FCS binding was seen in the absence of homocitrulline with peptide 77-87. Peptides corresponding to 76-90 D83 and 363-377 D367, 374 were superior at competing for binding to anti-CarP antibody-FCS. The 76-90 D83 or cyclized 77-87 D83 peptide mediated .30% inhibition in 26 (65%) of 40 sera tested. In this regard, the linear 76-90 D83 peptide was superior to the cyclized 76-87 D83 peptide for inhibiting anti-CarP antibody-FCS reactivity in this cohort ( Figure 1D ). These data potentially indicate the importance of additional C-terminal amino acids (amino acids 88-90) in anti-CarP antibody-FCS reactivity. In 12 sera (30%), none of the peptides mediated .30% inhibition.
Several patterns of peptide competition were observed. Some sera had competition with all carbamylated peptides (Figure 2A, patient 3) , suggesting reactivity against homocitrullines independent of context. One serum Figure 1 . Reactivity of patient sera to fibrinogen (fib). A, Carbamylated (carbam.) fibrinogen, citrullinated (cit.) fibrinogen, and native fibrinogen (1 mg/lane) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting was performed. Anti-carbamyl-lysine (anti-CBL) antibody detected carbamylated a-, b-, and g-chains of fibrinogen, while serum from the index patient, at 2 dilutions, identified specific reactivity to the b-chain of carbamylated, but not citrullinated or native, fibrinogen. B, Sera from patients with rheumatoid arthritis (n 5 63) were tested for reactivity to a specific fibrinogen b-chain peptide (peptide 77-87), with or without homocitrullinated lysine 83, by enzyme-linked immunosorbent assay (ELISA). Specific anti-carbamylated protein antibody (ACarPA) reactivity (with reactivity to native fetal calf serum [FCS] values subtracted) in relation to reactivity to fibrinogen 77-87 D83 (with reactivity to noncarbamylated peptide subtracted) is shown. C, Using the same data as that described in B, 6 outliers were removed in order to better see the distribution in patients with lower fibrinogen 77-87 D83 reactivity. D, The ability of the indicated peptides (at saturating concentrations of 50 mg/ml) to compete for binding with anti-CarP antibody-FCS was analyzed by ELISA, using patient sera (n 5 40) with the best anti-CarP reactivity. Horizontal lines show the median.
specimen exhibited striking specificity with near-complete inhibition of all anti-CarP antibody reactivity with the cyclized 77-87 D83 peptide ( Figure 2A, patient 2 ), but not with linear peptide 76-90 D83. There was little or no inhibition with the cyclized 77-87 peptide lacking homocitrulline. Along with other patient sera (patients 1, 4, and 5), either the cyclized 77-87 D83 peptide or the linear peptide 76-90 D83 peptide inhibited .50% of anti-CarP antibody-FCS reactivity.
These results suggest that in some patients, the carbamylated lysine at position 83 on the fibrinogen b-chain in this specific context represents a dominant epitope. This specificity was narrowed to amino acids 82-87 (QKKVER) given the poor conservation at the N-terminus in the bovine fibrinogen b-chain peptide. We also observed that the 363-377 D367, 374 peptide also provided significant competition. Inhibition by the 76-90 D83 peptide strongly correlated with that seen with 363-377 D367, 374 (R 5 0.59, P 5 0.0001) (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40098/abstract).
We then evaluated competition of these 2 peptides, singly or in combination, to determine whether these represent unique or cross-reactive epitopes ( Figure 2B ).
Despite the use of saturating levels of peptides, some patient sera were inhibited in an additive manner (patients 1, 3, 5, and 10), suggesting reactivity with distinct epitopes.
DISCUSSION
In the current study, we present data showing that specific peptides in the fibrinogen b-chain are a common target of anti-CarP antibodies. Using serum from an RA patient with anti-CarP antibodies specific to the b-chain of fibrinogen ( Figure 1A) , we identified strong reactivity to a homocitrulline at position 83. However, this was not the dominant reactive site in all RA patients, because we observed that only 35% of the RA patient sera had some level of reactivity to this peptide ( Figures 1B and C) . Therefore, we identified other peptides corresponding to carbamylated sites to which the index patient serum was reactive and evaluated their ability to compete with anti-CarP antibody-FCS ( Figure 1D ). Most sera with anti-CarP antibodies displayed reactivity to specific peptide sequences, e.g., they were not polyreactive with homocitrullines. This was also shown by immunoblotting ( Figure 1A and Supplementary Figure 1 Figure 1A . B, Competition analysis using peptides 76-90 D83, 363-377 D367, 374 or the combination in 10 patients with reactivity to both peptides. Each peptide concentration was 50 mg/ml (previous studies indicated that this concentration was maximally inhibitory) and was incubated for 1 hour with sera prior to adding to the ELISA. See Figure 1 for definitions.
wiley.com/doi/10.1002/art.40098/abstract), which additionally demonstrated predominant specificity for the fibrinogen b-chain in an additional 5 of 11 sera. Next, homocitrulline at position 83 of fibrinogen b-chain appeared to be a dominant epitope in several RA patients, most notably patients 1, 2, and 4 ( Figure 2A) . Finally, carbamylated lysines at positions 367 and 374 appeared to represent another dominant epitope, but only in patients whose serum also showed reactivity to the carbamylated lysine at position 83.
These observations prompt comment on anti-CarP antibody specificity. First, although some anti-CarP antibodies exhibit homocitrulline polyreactivity, most react with this posttranslational modification in the specific peptides found in the fibrinogen b-chain. Peptide competition studies demonstrated that 65% of all sera reactive with anti-CarP antibody-FCS could be competed with at least 1 of 5 homocitrulline-containing peptides ( Figures 1D and Figure  2 ). The degree of competition between peptides was variable, but in some patients this repertoire was remarkably specific and restricted to 1 or 2 epitopes. While an analysis of all possible carbamylated peptides in both linear and cyclized forms was not performed, the conclusions reached about fibrinogen b-chain specificity remain. It is possible that the remaining 35% of sera react with other homocitrullines found on the achain or g-chain of fibrinogen, but this has not been tested. Importantly, although these results suggest some degree of specificity, they do not directly address the issue of polyreactivity of individual anti-CarP antibodies, which would be more fully answered through the use of single anti-CarP monoclonal antibodies obtained from patients. Furthermore, our studies evaluated only IgG reactivity; studies of IgM or IgA antibodies may provide different perspectives.
Competition studies using intact fibrinogen have indicated that some, but not all, anti-CarP antibodies and ACPAs cross-react (13) . This notion of specific anti-CarP antibodies is consistent with their presence in ACPAnegative patients (9) as well as a lack of cross-reactivity, as shown by immunoblotting ( Figure 1A ). This study builds on these findings by demonstrating restriction of anti-CarP antibody reactivity to specific peptides in the human fibrinogen b-chain, thereby suggesting that some patients have antibodies specific for certain homocitrullinated peptides. Thus, we can now begin to ask questions about the specificity of the anti-CarP antibody response and its relationship to disease phenotype and outcome.
